Crinetics stock has been volatile but trending upward in 2025, with the recent FDA catalyst propelling it sharply higher. On September 26, 2025, CRNX closed around $45–$46, up roughly +28% in a single day reuters.com. This spike followed the Palsonify approval news and likely a short squeeze, given the high short interest prior to the decision marketbeat.com marketbeat.com. The one-year trading range spans $24.10 – $62.53 marketbeat.com, meaning the stock is now nearly double its 52-week low and about 26% below its 2023 high. In other words, even after the recent surge to the mid-$40s, CRNX trades mid-range of its past year’s spectrum.